NASDAQ:VVOS Vivos Therapeutics (VVOS) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free VVOS Stock Alerts $2.65 +0.01 (+0.38%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$2.60▼$2.7050-Day Range$2.64▼$5.8152-Week Range$2.40▼$48.79Volume35,657 shsAverage Volume190,029 shsMarket Capitalization$7.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vivos Therapeutics alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Vivos Therapeutics Stock (NASDAQ:VVOS)Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was founded in 2016 and is based in Littleton, Colorado.Read More VVOS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VVOS Stock News HeadlinesApril 15, 2024 | americanbankingnews.comTELA Bio (NASDAQ:TELA) vs. Vivos Therapeutics (NASDAQ:VVOS) Head-To-Head AnalysisApril 11, 2024 | proactiveinvestors.comVivos Therapeutics expects increased adoption of oral medical devices following Medicare reimbursement approvalApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 9, 2024 | finance.yahoo.comVivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical DevicesApril 9, 2024 | markets.businessinsider.comVivos Gets Approval To Facilitate Full Medicare Reimbursement For CARE Sleep Apnea Oral DevicesApril 9, 2024 | msn.comWhat's Going On With Vivos Therapeutics Stock?April 9, 2024 | msn.comMedicare to reimburse for Vivos CARE sleep apnea devicesApril 9, 2024 | proactiveinvestors.comVivos Therapeutics CARE oral medical devices approved for Medicare reimbursementApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 9, 2024 | investorplace.comWhy Is Vivos Therapeutics (VVOS) Stock Up 16% Today?April 9, 2024 | msn.comVivos Therapeutics files to sell 1.73M shares of common stock for holdersApril 9, 2024 | finance.yahoo.comVivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementApril 9, 2024 | globenewswire.comVivos Therapeutics' Flagship CARE Oral Medical Devices Receive Full Approval for Medicare ReimbursementApril 1, 2024 | proactiveinvestors.comVivos Therapeutics highlights path to cash flow positivity after FDA clearanceMarch 31, 2024 | finance.yahoo.comVivos Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 30, 2024 | seekingalpha.comVivos Therapeutics, Inc. (VVOS) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | marketwatch.comVivos Therapeutics Shares Fall After Wider-Than-Expected 4Q LossMarch 28, 2024 | globenewswire.comVivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational UpdateMarch 28, 2024 | globenewswire.comVivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference CallFebruary 22, 2024 | benzinga.comVivos Therapeutics Stock (NASDAQ:VVOS), Short Interest ReportFebruary 22, 2024 | benzinga.comVivos Therapeutics Stock (NASDAQ:VVOS) Insider TradesFebruary 18, 2024 | investing.comVivos Therapeutics secures $4 million through warrant exerciseFebruary 15, 2024 | finance.yahoo.comVivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross ProceedsFebruary 15, 2024 | proactiveinvestors.comVivos Therapeutics sees gross proceeds of $4M from exercise of warrantFebruary 12, 2024 | finance.yahoo.comVivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market DisruptionsFebruary 6, 2024 | finanznachrichten.deVivos Therapeutics, Inc: Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesFebruary 6, 2024 | finance.yahoo.comVivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth OpportunitiesSee More Headlines Receive VVOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/23/2024Next Earnings (Estimated)6/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:VVOS CUSIPN/A CIK1716166 Webwww.vivoslife.com Phone866-908-4867FaxN/AEmployees154Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($11.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,580,000.00 Net Margins-98.42% Pretax Margin-98.42% Return on Equity-665.17% Return on Assets-122.48% Debt Debt-to-Equity RatioN/A Current Ratio0.34 Quick Ratio0.34 Sales & Book Value Annual Sales$13.80 million Price / Sales0.52 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book12.05Miscellaneous Outstanding Shares2,730,000Free Float2,469,000Market Cap$7.23 million OptionableOptionable Beta7.95 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. R. Kirk Huntsman (Age 66)Co-Founder, Chairman of the Board & CEO Comp: $482.16kMr. Bradford K. Amman (Age 62)CFO, Treasurer & Secretary Comp: $335.53kMr. Todd HuntsmanCo-Founder & Senior VP of Product and TechnologyMs. RaeAnn ByrnesCo-Founder and Senior VP of Events & Clinical Advisory ServicesMs. Susan McCulloughCo-Founder & Executive VP of OperationsMs. Julie GannonSenior VP of Strategic Sales & Marketing and Investor Relations OfficerMr. Nicholas M. DeGennaroSenior Vice President of Medical Integration DivisionMs. Ruth HembreeSenior Vice President of Practice ServicesMs. Stephanie HuebnerSenior Vice President of Dental Service IntegrationMr. John BallardSenior Vice President of TechnologyMore ExecutivesKey CompetitorsPlus TherapeuticsNASDAQ:PSTVVapothermNYSE:VAPOIntelligent Bio SolutionsNASDAQ:INBSAvingerNASDAQ:AVGRNeuroMetrixNASDAQ:NUROView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 57,000 shares on 2/13/2024Ownership: 4.286%Ronald Kirk HuntsmanBought 560 shares on 6/20/2023Total: $7,420.00 ($13.25/share)Ronald Kirk HuntsmanBought 600 shares on 6/16/2023Total: $8,100.00 ($13.50/share)Ronald Kirk HuntsmanBought 400 shares on 6/14/2023Total: $4,900.00 ($12.25/share)View All Insider TransactionsView All Institutional Transactions VVOS Stock Analysis - Frequently Asked Questions How have VVOS shares performed in 2024? Vivos Therapeutics' stock was trading at $12.44 at the beginning of 2024. Since then, VVOS shares have decreased by 78.7% and is now trading at $2.65. View the best growth stocks for 2024 here. Are investors shorting Vivos Therapeutics? Vivos Therapeutics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 18,700 shares, a decrease of 28.6% from the March 15th total of 26,200 shares. Based on an average daily volume of 208,400 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.8% of the shares of the stock are sold short. View Vivos Therapeutics' Short Interest. When is Vivos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 13th 2024. View our VVOS earnings forecast. How were Vivos Therapeutics' earnings last quarter? Vivos Therapeutics, Inc. (NASDAQ:VVOS) announced its quarterly earnings results on Thursday, March, 28th. The company reported ($3.05) EPS for the quarter. The company earned $3.25 million during the quarter. Vivos Therapeutics had a negative net margin of 98.42% and a negative trailing twelve-month return on equity of 665.17%. When did Vivos Therapeutics' stock split? Vivos Therapeutics's stock reverse split on the morning of Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Vivos Therapeutics IPO? Vivos Therapeutics (VVOS) raised $20 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 3,300,000 shares at $5.00-$7.00 per share. Roth Capital Partners served as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers. How do I buy shares of Vivos Therapeutics? Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VVOS) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
